Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Gilead Sciences Trading Up 1.2 %
NASDAQ:GILD opened at $98.38 on Tuesday. The business’s 50-day moving average is $92.42 and its two-hundred day moving average is $85.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $99.45. The firm has a market capitalization of $122.61 billion, a PE ratio of 1,093.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the company posted $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.
Institutional Trading of Gilead Sciences
Wall Street Analysts Forecast Growth
Several research firms have weighed in on GILD. Oppenheimer raised their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Mizuho raised their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Finally, Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.
Get Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- What is a support level?
- How to Invest in Small Cap Stocks
- How to Use the MarketBeat Dividend Calculator
- These Are the Dividend Stocks Insiders Bought in January
- What is diluted earnings per share (Diluted EPS)?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.